Next, we explored if upregulation of IL-7Rα is functionally important for combination therapy-induced tumour rejection by inoculating Il7r−/− mice, deficient of IL-7Rα with MB49 tumour cells, followed by combination therapy. This evidence concerns the gene IL7R and neoplasm.